Antivirals buoy Gilead Sciences' profits
This article was originally published in Scrip
Executive Summary
Gilead Sciences' second-quarter profits have increased by 31% to $571.4 million on the back of double-digit growth of its antiviral franchise. The division grew by 26% to $1.41 billion following robust sales of its HIV treatments.